2.81
price up icon13.77%   0.34
after-market 시간 외 거래: 2.91 0.10 +3.56%
loading
전일 마감가:
$2.47
열려 있는:
$2.51
하루 거래량:
3.08M
Relative Volume:
1.77
시가총액:
$289.65M
수익:
-
순이익/손실:
$-134.24M
주가수익비율:
-1.5876
EPS:
-1.77
순현금흐름:
$-121.34M
1주 성능:
+17.57%
1개월 성능:
+32.55%
6개월 성능:
-48.91%
1년 성능:
-38.44%
1일 변동 폭
Value
$2.46
$2.98
1주일 범위
Value
$2.30
$2.98
52주 변동 폭
Value
$1.285
$7.85

아넥손 Stock (ANNX) Company Profile

Name
명칭
Annexon Inc
Name
전화
(650)-822-5500
Name
주소
1400 SIERRA POINT PARKWAY, BRISBANE
Name
직원
100
Name
트위터
Name
다음 수익 날짜
2024-11-11
Name
최신 SEC 제출 서류
Name
ANNX's Discussions on Twitter

ANNX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ANNX
Annexon Inc
2.81 289.65M 0 -134.24M -121.34M -1.77
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

아넥손 Stock (ANNX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-03-01 업그레이드 JP Morgan Neutral → Overweight
2023-12-21 업그레이드 BofA Securities Neutral → Buy
2023-10-30 개시 Wells Fargo Overweight
2023-05-26 다운그레이드 BofA Securities Buy → Neutral
2023-05-25 다운그레이드 JP Morgan Overweight → Neutral
2022-09-16 개시 Jefferies Buy
2022-09-09 개시 BTIG Research Buy
2021-11-30 개시 H.C. Wainwright Buy
2021-09-23 개시 Cantor Fitzgerald Overweight
2021-01-26 개시 Needham Buy
2020-08-18 개시 BofA Securities Buy
2020-08-18 개시 Cowen Outperform
2020-08-18 개시 JP Morgan Overweight
모두보기

아넥손 주식(ANNX)의 최신 뉴스

pulisher
Jun 18, 2025

Annexon says enrollment of Phase 3 Archer II Trial expected to be completed in Q3 2025 - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrop - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) - GlobeNewswire

Jun 18, 2025
pulisher
Jun 17, 2025

Bank of America Corp DE Sells 137,220 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World

Jun 17, 2025
pulisher
Jun 17, 2025

Annexon, Inc. (NASDAQ:ANNX) Shares Sold by Park Avenue Securities LLC - Defense World

Jun 17, 2025
pulisher
Jun 16, 2025

Market Highlights: Annexon Inc (ANNX) Ends on a Low Note at 2.49 - DWinneX

Jun 16, 2025
pulisher
Jun 13, 2025

Annexon Inc (ANNX) Stock: A Comprehensive 52-Week Review - investchronicle.com

Jun 13, 2025
pulisher
Jun 13, 2025

49,062 Shares in Annexon, Inc. (NASDAQ:ANNX) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 13, 2025
pulisher
Jun 13, 2025

Annexon, Inc. (NASDAQ:ANNX) Shares Bought by California State Teachers Retirement System - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald Estimates Annexon FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 09, 2025

Annexon Biosciences Holds Annual Stockholders Meeting - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Two Sigma Advisers LP Reduces Stock Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Squarepoint Ops LLC Sells 49,438 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Millennium Management LLC Grows Stake in Annexon, Inc. (NASDAQ:ANNX) - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Transcript : Annexon, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 08 - marketscreener.com

Jun 05, 2025
pulisher
Jun 03, 2025

Huntington’s Disease Clinical Trial Pipeline Analysis: 20+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight - GlobeNewswire Inc.

Jun 03, 2025
pulisher
Jun 03, 2025

BNP Paribas Financial Markets Makes New $59,000 Investment in Annexon, Inc. (NASDAQ:ANNX) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

ProShare Advisors LLC Buys 14,475 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World

Jun 02, 2025
pulisher
May 30, 2025

Annexon, Inc. (NASDAQ:ANNX) Shares Bought by Jane Street Group LLC - Defense World

May 30, 2025
pulisher
May 29, 2025

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference | ANNX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference - GlobeNewswire

May 29, 2025
pulisher
May 26, 2025

Nuveen Asset Management LLC Acquires 164,915 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World

May 26, 2025
pulisher
May 26, 2025

Janus Henderson Group PLC Invests $177,000 in Annexon, Inc. (NASDAQ:ANNX) - Defense World

May 26, 2025
pulisher
May 25, 2025

Annexon, Inc. (NASDAQ:ANNX) Stock Holdings Raised by Ameriprise Financial Inc. - Defense World

May 25, 2025
pulisher
May 22, 2025

Deutsche Bank AG Acquires 28,448 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World

May 22, 2025
pulisher
May 21, 2025

Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Northern Trust Corp - Defense World

May 21, 2025
pulisher
May 20, 2025

Annexon reports promising Guillain-Barré treatment results By Investing.com - Investing.com India

May 20, 2025
pulisher
May 19, 2025

Annexon (ANNX) Highlights Promising Results from Tanruprubart Ph - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Annexon reports promising Guillain-Barré treatment results - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

Annexon Showcases Tanruprubart Data Demonstrating Improved Clini - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Annexon Showcases Tanruprubart Data Demonstrating Improved - GlobeNewswire

May 19, 2025
pulisher
May 19, 2025

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting - The Manila Times

May 19, 2025
pulisher
May 19, 2025

New GBS Drug Shows 3X Better Outcomes Than Standard Care in Clinical Trial | ANNX Stock News - Stock Titan

May 19, 2025
pulisher
May 19, 2025

Annexon Inc (NASDAQ: ANNX) Stock Sentiment: What’s Wall Street Saying? - Stocksregister

May 19, 2025
pulisher
May 17, 2025

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 17, 2025
pulisher
May 16, 2025

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) | ANNX Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Annexon Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Annexon Awards $387K Worth of Stock Options to New Hires: Inside the Compensation Package - Stock Titan

May 16, 2025
pulisher
May 16, 2025

HC Wainwright Issues Negative Estimate for Annexon Earnings - Defense World

May 16, 2025
pulisher
May 16, 2025

HC Wainwright Has Lowered Expectations for Annexon (NASDAQ:ANNX) Stock Price - Defense World

May 16, 2025
pulisher
May 15, 2025

Needham & Company LLC Has Lowered Expectations for Annexon (NASDAQ:ANNX) Stock Price - Defense World

May 15, 2025
pulisher
May 14, 2025

Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga

May 14, 2025
pulisher
May 14, 2025

Annexon (ANNX) Receives Revised Price Target from HC Wainwright - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Schonfeld Strategic Advisors LLC Sells 589,091 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World

May 14, 2025
pulisher
May 13, 2025

Cantor Fitzgerald maintains Overweight on Annexon stock By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

Annexon (ANNX) Sees Price Target Cut to $14 by H.C. Wainwright | - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Annexon Inc Reports Q1 2025 EPS of -$0.37, Missing Estimates; Re - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Annexon (ANNX) Maintains "Buy" Rating Despite Price Target Cut | ANNX Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Annexon Biosciences Reports Increased Q1 2025 Losses - TipRanks

May 13, 2025
pulisher
May 12, 2025

Annexon, Inc. SEC 10-Q Report - TradingView

May 12, 2025
pulisher
May 12, 2025

Annexon Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025

아넥손 (ANNX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

아넥손 주식 (ANNX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
ARTIS DEAN RICHARD
EVP & CHIEF SCIENTIFIC OFFICER
Feb 18 '25
Sale
2.97
5,515
16,380
83,814
Yednock Ted
EVP & CHIEF INNOVATION OFFICER
Feb 18 '25
Sale
2.91
8,345
24,284
61,237
Overdorf Michael
EVP & CHIEF BUSINESS OFFICER
Feb 18 '25
Sale
2.95
6,618
19,523
86,579
Lew Jennifer
EVP & CHIEF FINANCIAL OFFICER
Feb 18 '25
Sale
2.92
6,912
20,183
77,770
Love Douglas
PRESIDENT AND CEO
Feb 13 '25
Sale
2.95
5,021
14,812
351,554
Lew Jennifer
EVP & CHIEF FINANCIAL OFFICER
Feb 13 '25
Sale
2.98
1,786
5,322
84,682
Overdorf Michael
EVP & CHIEF BUSINESS OFFICER
Feb 13 '25
Sale
2.99
1,425
4,261
93,197
Yednock Ted
EVP & CHIEF INNOVATION OFFICER
Feb 13 '25
Sale
2.99
1,783
5,331
69,582
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
자본화:     |  볼륨(24시간):